To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have NHL that has returned or continued to grow despite standard therapy that included rituximab.
- Patients with T-cell lymphoma may not participate.
- There is no limit on the number of prior treatments, but patients should have recovered from the serious side effects of therapy before entering the study.
- Patients must be able to be ambulatory for more than half of their normal waking hours.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. M. Lia Palomba at 212-639-7186.